- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
SCLC treatment market value to rise to $2.29b by 2024, says GlobalData
22 January 2016 • Author: Victoria White
The Small Cell Lung Cancer (SCLC) treatment market will rise dramatically from $198 million in 2014 to $2.29 billion by 2024, according to research and consulting firm GlobalData.
The company’s latest report, OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) – Opportunity Analysis and Forecasts to 2024, states that such impressive growth will primarily be driven by the launch of premium-priced therapies, including anti-PD-1 and anti-CTLA-4 immunotherapies and targeted agents.
Volkan Gunduz, Ph.D., GlobalData’s Analyst covering Oncology and Haematology, says novel SCLC therapies will experience strong and rapid adoption during the forecast period in combination with generic, chemotherapy-only regimens in the early lines of therapy, and extend the number of lines of treatment available for patients.
Gunduz explains: “The first immunotherapy to market will be the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor Yervoy. This drug is being developed by Bristol-Myers Squibb and will be launched in 2016 across the 7MM.
“Yervoy will achieve blockbuster status in the SCLC therapeutics space by 2024, driven by the combination of its premium price and anticipated dosing at a high concentration in combination with platinum-etoposide in extensive-stage SCLC.”
SLCL disease incidence expected to ‘plateau’ by 2024
GlobalData’s report also states that SCLC treatment sales will also be bolstered by an increase in rates of the disease across the five European markets and Japan over the forecast period.
Gunduz continues: “While smoking is by far the leading risk factor for lung cancer and is still a common practice in Eastern Europe and in developing countries, disease incidence is expected to plateau by 2024.
“This will occur as the five European markets and Japan follow in the footsteps of the US, where a reduction in cigarette smoking has caused SCLC incidence rates to decrease considerably over the last three decades. In this way, although the SCLC treatment market will thrive in the short term, its impressive growth may not continue beyond this point.”
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics